Literature DB >> 29708808

MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.

Ayalew Tefferi1, Paola Guglielmelli1, Terra L Lasho1, Naseema Gangat1, Rhett P Ketterling1, Animesh Pardanani1, Alessandro M Vannucchi1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29708808     DOI： 10.1200/JCO.2018.78.9867

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  57 in total

1.  MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Authors:  Haris Ali; Ibrahim Aldoss; Dongyun Yang; Sally Mokhtari; Samer Khaled; Ahmed Aribi; Michelle Afkhami; Monzr M Al Malki; Thai Cao; Matthew Mei; Margaret O'Donnell; Amandeep Salhotra; Vinod Pullarkat; Lixin Yang; Anthony S Stein; Guido Marcucci; Stephen J Forman; Ryotaro Nakamura; Raju Pillai; David Snyder
Journal:  Blood Adv       Date:  2019-01-08

2.  Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.

Authors:  Roni Shouval; Yakov Vega; Joshua A Fein; Ivetta Danylesko; Noga Shem Tov; Ronit Yerushalmi; Marta Sobas; Anna Czyż; Arnon Nagler; Avichai Shimoni
Journal:  Bone Marrow Transplant       Date:  2019-08-28       Impact factor: 5.483

3.  Mutant calreticulin in myeloproliferative neoplasms.

Authors:  Joan How; Gabriela S Hobbs; Ann Mullally
Journal:  Blood       Date:  2019-12-19       Impact factor: 22.113

Review 4.  Mutational profiling in myelofibrosis: implications for management.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2019-10-19       Impact factor: 2.490

Review 5.  Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?

Authors:  Alain Antoine Mina; Brady Stein
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

6.  Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.

Authors:  Aaron T Gerds; Michael R Savona; Bart L Scott; Moshe Talpaz; Miklos Egyed; Claire N Harrison; Abdulraheem Yacoub; Alessandro Vannucchi; Adam J Mead; Jean-Jacques Kiladjian; Jennifer O'Sullivan; Valentin García-Gutiérrez; Prithviraj Bose; Raajit K Rampal; Carole B Miller; Jeanne Palmer; Stephen T Oh; Sarah A Buckley; Diane R Mould; Kaori Ito; Shanthakumar Tyavanagimatt; Jennifer A Smith; Karisse Roman-Torres; Sri Devineni; Adam R Craig; John O Mascarenhas
Journal:  Blood Adv       Date:  2020-11-24

7.  Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN.

Authors:  Aaron T Gerds
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 8.  Leukemia secondary to myeloproliferative neoplasms.

Authors:  Andrew J Dunbar; Raajit K Rampal; Ross Levine
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 9.  Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.

Authors:  Daniel R Richardson; Steven D Green; Matthew C Foster; Joshua F Zeidner
Journal:  Curr Hematol Malig Rep       Date:  2021-02-20       Impact factor: 3.952

10.  Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.

Authors:  Lucia Masarova; Prithviraj Bose; Naveen Pemmaraju; Naval G Daver; Lingsha Zhou; Sherry Pierce; Koji Sasaki; Hagop M Kantarjian; Zeev Estrov; Srdan Verstovsek
Journal:  Cancer       Date:  2020-07-22       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.